FutureChem

퓨쳐켐 · 220100

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$196.6M (₩271.4B)

Overview

FutureChem develops radiopharmaceuticals, medicines that attach a radioactive isotope to a targeting molecule so doctors can both image and treat diseases such as prostate cancer, Alzheimer's disease, and brain tumours.

Its products are used in nuclear-medicine departments at hospitals and clinics. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds approved diagnostic drugs as well as a pipeline of therapeutic candidates, with its commercial revenue anchored in its approved imaging agents while later-stage treatment drugs remain in development.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$13.5M

▲ +8.0% YoY

Operating profit · FY2025

−US$5.6M

Loss narrowed

Net income · FY2025

US$31.5K

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$10.1M(₩14B)	US$12.5M(₩17.3B)	US$13.5M(₩18.7B)
Operating profit	−US$6.1M(−₩8.4B)	−US$6.9M(−₩9.5B)	−US$5.6M(−₩7.8B)
Net income	−US$4.9M(−₩6.7B)	−US$6.8M(−₩9.4B)	US$31.5K(₩43.4M)

Revenue

FY2023US$10.1M
FY2024US$12.5M
FY2025US$13.5M

Operating profit

FY2023−US$6.1M
FY2024−US$6.9M
FY2025−US$5.6M

Net income

FY2023−US$4.9M
FY2024−US$6.8M
FY2025US$31.5K

Key ratios (FY2025)

ROE

0.1%

Debt/Eq

35.9%

Op. margin

-41.5%

Net margin

0.2%

Rev. YoY

▲ +8.0%

Why it matters

The company operates its own proprietary automated synthesis device, branded sCUBE®, which it developed in-house to manufacture radiopharmaceuticals under pharmaceutical-grade production standards.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?